AAAAAA
Results:
1-11
|
Results: 11
Authors:
Kern, W
Schleyer, E
Braess, J
Wittmer, E
Ohnesorge, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone [FIS-HAM] salvage therapy in highly resistant acuteleukemias, ANN HEMATOL, 80(6), 2001, pp. 334-339
Authors:
Kern, W
Braess, J
Friedrichsen, S
Kaufmann, CC
Schleyer, E
Hiddemann, W
Citation: W. Kern et al., Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve, J CANC RES, 127(1), 2001, pp. 64-68
Authors:
Braess, J
Jahns-Streubel, G
Schoch, C
Haase, D
Haferlach, T
Fiegl, M
Voss, S
Kern, W
Schleyer, E
Hiddemann, W
Citation: J. Braess et al., Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroupsin acute myeloid leukaemia, BR J HAEM, 113(4), 2001, pp. 975-982
Authors:
Braess, J
Jahns-Streubel, G
Voss, S
Kern, W
Keye, S
Schleyer, E
Hiddemann, W
Citation: J. Braess et al., The endogenous leukemic proliferation rate and cytosine arabinoside pharmacodynamics are major determinants for therapeutic success in acute myeloid leukemia, INT J CL PH, 38(3), 2000, pp. 150-151
Authors:
Kern, W
Friedrichsen, S
Kaufmann, CC
Schleyer, E
Hiddemann, W
Braess, J
Citation: W. Kern et al., Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve, INT J CL PH, 38(3), 2000, pp. 152-152
Authors:
Schleyer, E
Rudolph, KL
Braess, J
Unterhalt, M
Ehninger, G
Hiddemann, W
Kern, W
Citation: E. Schleyer et al., Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid, CANC CHEMOT, 45(2), 2000, pp. 165-171
Authors:
Braess, J
Voss, S
Jahns-Streubel, G
Schoch, C
Haferlach, T
Kern, W
Keye, S
Schleyer, E
Hiddemann, W
Citation: J. Braess et al., The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with ahigh proliferative activity, BR J HAEM, 110(1), 2000, pp. 170-179
Authors:
Braess, J
Wegendt, C
Jahns-Streubel, G
Kern, W
Keye, S
Unterhalt, M
Schleyer, E
Hiddemann, W
Citation: J. Braess et al., Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine, BR J HAEM, 109(2), 2000, pp. 388-395
Authors:
Kern, W
Braess, J
Bottger, B
Kaufmann, CC
Hiddemann, W
Schleyer, E
Citation: W. Kern et al., Oxaliplatin pharmacokinetics during a four-hour infusion, CLIN CANC R, 5(4), 1999, pp. 761-765
Authors:
Braess, J
Pfortner, J
Kern, W
Hiddemann, W
Schleyer, E
Citation: J. Braess et al., Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells, ANN HEMATOL, 78(11), 1999, pp. 514-520
Authors:
Braess, J
Wegendt, C
Feuring-Buske, M
Riggert, J
Kern, W
Hiddemann, W
Schleyer, E
Citation: J. Braess et al., Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34(+) haemopoietic stem cells in their metabolism of cytosine arabinoside, BR J HAEM, 105(2), 1999, pp. 388-393
Risultati:
1-11
|